carvedilol has been researched along with Disease Exacerbation in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol is effective in the primary prophylaxis for large oesophageal varices." | 9.24 | Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. ( Bhadoria, AS; Bhardwaj, A; Bhatia, V; Choudhary, A; Jindal, A; Kedarisetty, CK; Kumar, G; Kumar, M; Maiwall, R; Sarin, SK; Shasthry, SM; Vashishtha, C, 2017) |
| "Carvedilol treatment in chronic heart failure (CHF) demonstrated to reduce mortality and rehospitalisation, and improvement of cardiac systolic function with reduction of left ventricular volumes and remodelling." | 9.11 | Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure. ( De Paola, V; Iovine, F; Martini, G; Nuti, R; Palazzuoli, A; Quatrini, I; Scali, C; Vecchiato, L, 2005) |
| "Carvedilol added to angiotensin-converting enzyme inhibition reduces hospitalization risk as well as severity of illness and resource utilization during admission in patients with chronic heart failure." | 7.71 | Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Lacey, MJ; Lukas, MA; Oster, G; Packer, M; Richner, R; Vera-Llonch, M; Young, ST, 2001) |
| "Carvedilol is a novel multiple-action neurohormonal antagonist that has been shown to be effective in the management of congestive heart failure." | 6.40 | Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1998) |
| "Carvedilol is effective in the primary prophylaxis for large oesophageal varices." | 5.24 | Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. ( Bhadoria, AS; Bhardwaj, A; Bhatia, V; Choudhary, A; Jindal, A; Kedarisetty, CK; Kumar, G; Kumar, M; Maiwall, R; Sarin, SK; Shasthry, SM; Vashishtha, C, 2017) |
| "The effect of the beta-blocker, carvedilol, and/or ACEI on ventricular function in patients with muscular dystrophy was studied." | 5.12 | Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. ( Ishigaki, K; Kajimoto, H; Nakanishi, T; Nakazawa, M; Okumura, K; Osawa, M; Saito, K; Tomimatsu, H, 2006) |
| "Carvedilol treatment in chronic heart failure (CHF) demonstrated to reduce mortality and rehospitalisation, and improvement of cardiac systolic function with reduction of left ventricular volumes and remodelling." | 5.11 | Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure. ( De Paola, V; Iovine, F; Martini, G; Nuti, R; Palazzuoli, A; Quatrini, I; Scali, C; Vecchiato, L, 2005) |
| "The historical choice of angiotensin-converting enzyme (ACE) inhibition as first-line therapy in heart failure is challenged by early activation of the sympathetic system and multiple ways beta blockade (in particular, unselective agents such as carvedilol) may affect cardiac remodeling, its underlying mechanisms, and, hence, progression of heart failure, compared with ACE inhibition." | 4.84 | Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first? ( Remme, WJ, 2007) |
| "Carvedilol added to angiotensin-converting enzyme inhibition reduces hospitalization risk as well as severity of illness and resource utilization during admission in patients with chronic heart failure." | 3.71 | Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Lacey, MJ; Lukas, MA; Oster, G; Packer, M; Richner, R; Vera-Llonch, M; Young, ST, 2001) |
| "The cardioprotective properties of carvedilol (a vasodilating beta-adrenoceptor blocking agent) were studied in a rat model of dilated cardiomyopathy induced by autoimmune myocarditis." | 3.70 | Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. ( Aizawa, Y; Fuse, K; Hanawa, H; Hasegawa, G; Higuchi, H; Hirono, S; Ito, M; Kato, K; Kodama, M; Naito, M; Nakazawa, M; Ohta, Y; Tanabe, N; Watanabe, K, 2000) |
| "Fatigue, but not breathlessness, remained a significant predictor for developing worsening heart failure (RR 1." | 2.71 | Symptoms in patients with heart failure are prognostic predictors: insights from COMET. ( Charlesworth, A; Cleland, JG; Ekman, I; Metra, M; Poole-Wilson, PA; Swedberg, K, 2005) |
| "Carvedilol treatment had a beneficial effect on lipid pattern and reduced lipid oxidation, but there was no obvious effect on progression of chronic rejection." | 2.69 | Carvedilol treatment of kidney graft recipients with chronic rejection. ( Backman, U; Fellström, B; Larsson, E; Vessby, B; Zezina, L, 1999) |
| "Carvedilol reduced all-cause mortality but had no effects on the Minnesota Living With Heart Failure scale, the distance walked in 9 minutes on a self-powered treadmill, or cardiothoracic index." | 2.68 | Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. ( Bowers, JA; Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Hershberger, R; Holcslaw, TL; Krueger, SK; Lukas, MA; Packer, M; Sackner-Bernstein, JD; Uretsky, BF; Young, ST, 1996) |
| "β-blockers are an important treatment of heart failure (HF) and are useful in reducing the progression of the syndrome." | 2.48 | β-blockers in stage B: a precursor of heart failure. ( Francis, GS; Sarraf, M, 2012) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| "This ability to decrease the risk of disease progression led to the recent approval of carvedilol for the treatment of chronic heart failure by the US Food and Drug Administration." | 2.40 | Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. ( Packer, M, 1997) |
| "Carvedilol is a novel multiple-action neurohormonal antagonist that has been shown to be effective in the management of congestive heart failure." | 2.40 | Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1998) |
| "Carvedilol is a multiple-action neurohormonal antagonist that is effective in slowing the progression of CHF." | 2.40 | Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1998) |
| "Patients with hypertension are at increased risk of developing heart failure (HF), but the mechanisms by which hypertension leads to HF have not been clarified [although left ventricular hypertrophy (LVH) is clearly a predictor of an increased risk of HF]." | 2.40 | Progression from hypertension to heart failure. Mechanisms and management. ( Cleland, JG, 1999) |
| "Furthermore, beta-blockers delay disease progression in CHF by reversing the pathological myocardial remodelling process that accompanies the disease." | 2.40 | Sympathetic activation and the role of beta-blockers in chronic heart failure. ( Krum, H, 1999) |
| "In patients with concurrent CHF and COPD, β-blockers reduced mortality, CHF exacerbation, and the need for hospitalization." | 1.46 | The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. ( Chen, CY; Huang, YB; Kuo, CC; Liao, KM; Lin, TY, 2017) |
| "Moreover, the rate of CHF and/or COPD exacerbation was higher in patients treated with carvedilol compared with bisoprolol (log-rank P=0." | 1.42 | Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. ( Asai, K; Furuse, E; Kubota, Y; Murai, K; Nakamura, S; Shimizu, W; Tsukada, YT, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (20.59) | 18.2507 |
| 2000's | 17 (50.00) | 29.6817 |
| 2010's | 9 (26.47) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, S | 1 |
| Imamura, T | 1 |
| Ueno, H | 1 |
| Kinugawa, K | 1 |
| Moser-Bracher, A | 1 |
| Balmer, C | 1 |
| Cavigelli, A | 1 |
| Satir, A | 1 |
| Caduff Good, A | 1 |
| Klauwer, D | 1 |
| Liao, KM | 1 |
| Lin, TY | 1 |
| Huang, YB | 1 |
| Kuo, CC | 1 |
| Chen, CY | 1 |
| Fonarow, G | 1 |
| Textor, SC | 1 |
| Rea, G | 1 |
| Valente, T | 1 |
| de Rosa, N | 1 |
| Muto, M | 1 |
| Berritto, D | 1 |
| Bocchino, M | 1 |
| Kubota, Y | 1 |
| Asai, K | 1 |
| Furuse, E | 1 |
| Nakamura, S | 1 |
| Murai, K | 1 |
| Tsukada, YT | 1 |
| Shimizu, W | 1 |
| Bhardwaj, A | 1 |
| Kedarisetty, CK | 1 |
| Vashishtha, C | 1 |
| Bhadoria, AS | 1 |
| Jindal, A | 1 |
| Kumar, G | 1 |
| Choudhary, A | 1 |
| Shasthry, SM | 1 |
| Maiwall, R | 1 |
| Kumar, M | 1 |
| Bhatia, V | 1 |
| Sarin, SK | 1 |
| Crespo, MJ | 1 |
| Cruz, N | 1 |
| Altieri, PI | 1 |
| Escobales, N | 1 |
| Sehnert, AJ | 1 |
| Daniels, SE | 1 |
| Elashoff, M | 1 |
| Wingrove, JA | 1 |
| Burrow, CR | 1 |
| Horne, B | 1 |
| Muhlestein, JB | 1 |
| Donahue, M | 1 |
| Liggett, SB | 1 |
| Anderson, JL | 1 |
| Kraus, WE | 1 |
| Jovanovic, D | 2 |
| Jovovic, D | 2 |
| Mihailovic-Stanojevic, N | 2 |
| Miloradovic, Z | 2 |
| Naumovic, R | 1 |
| Dimitrijevic, J | 2 |
| Maksic, N | 2 |
| Djukanovic, L | 2 |
| Barison, A | 1 |
| Aquaro, GD | 1 |
| Passino, C | 1 |
| Falorni, M | 1 |
| Balbarini, A | 1 |
| Lombardi, M | 1 |
| Pasquali, L | 1 |
| Emdin, M | 1 |
| Siciliano, G | 1 |
| Pedersen, ME | 1 |
| Cockcroft, JR | 1 |
| Remme, WJ | 2 |
| Sarraf, M | 1 |
| Francis, GS | 1 |
| Liu, J | 1 |
| Takase, I | 1 |
| Hakucho, A | 1 |
| Okamura, N | 1 |
| Fujimiya, T | 1 |
| Abraham, WT | 2 |
| Gilbert, EM | 3 |
| Lowes, BD | 1 |
| Minobe, WA | 1 |
| Larrabee, P | 1 |
| Roden, RL | 1 |
| Dutcher, D | 1 |
| Sederberg, J | 1 |
| Lindenfeld, JA | 1 |
| Wolfel, EE | 1 |
| Shakar, SF | 1 |
| Ferguson, D | 1 |
| Volkman, K | 1 |
| Linseman, JV | 1 |
| Quaife, RA | 1 |
| Robertson, AD | 1 |
| Bristow, MR | 3 |
| Ekman, I | 1 |
| Cleland, JG | 2 |
| Swedberg, K | 1 |
| Charlesworth, A | 1 |
| Metra, M | 1 |
| Poole-Wilson, PA | 1 |
| Naccarelli, GV | 1 |
| Palazzuoli, A | 1 |
| Quatrini, I | 1 |
| Vecchiato, L | 1 |
| Scali, C | 1 |
| De Paola, V | 1 |
| Iovine, F | 1 |
| Martini, G | 1 |
| Nuti, R | 1 |
| Kajimoto, H | 1 |
| Ishigaki, K | 1 |
| Okumura, K | 1 |
| Tomimatsu, H | 1 |
| Nakazawa, M | 2 |
| Saito, K | 1 |
| Osawa, M | 1 |
| Nakanishi, T | 1 |
| Colucci, WS | 2 |
| Packer, M | 3 |
| Cohn, JN | 2 |
| Fowler, MB | 2 |
| Krueger, SK | 1 |
| Hershberger, R | 1 |
| Uretsky, BF | 1 |
| Bowers, JA | 1 |
| Sackner-Bernstein, JD | 1 |
| Young, ST | 2 |
| Holcslaw, TL | 1 |
| Lukas, MA | 2 |
| Ruffolo, RR | 2 |
| Feuerstein, GZ | 2 |
| Zezina, L | 1 |
| Vessby, B | 1 |
| Larsson, E | 1 |
| Backman, U | 1 |
| Fellström, B | 1 |
| Krum, H | 1 |
| Watanabe, K | 1 |
| Ohta, Y | 1 |
| Higuchi, H | 1 |
| Hasegawa, G | 1 |
| Naito, M | 1 |
| Fuse, K | 1 |
| Ito, M | 1 |
| Hirono, S | 1 |
| Tanabe, N | 1 |
| Hanawa, H | 1 |
| Kato, K | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Vera-Llonch, M | 1 |
| Oster, G | 1 |
| Lacey, MJ | 1 |
| Richner, R | 1 |
| Czuriga, I | 1 |
| Edes, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Early Primary Prophylaxis of Esophageal Varices in Cirrhosis.[NCT01196507] | 140 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Transient Elastography (FibroTouch) for Assessing Risk of Gastroesophageal Varices Bleeding in Patients With Compensated Cirrhosis (Pan-CHESS1801): An International Multicenter Study[NCT03778775] | 200 participants (Anticipated) | Observational | 2018-12-14 | Recruiting | |||
| Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study[NCT05597709] | 2,900 participants (Anticipated) | Observational | 2022-07-01 | Recruiting | |||
| Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study[NCT04543643] | Phase 3 | 288 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS1801): A Prospective Multicenter Study[NCT03749954] | 105 participants (Actual) | Observational | 2018-11-09 | Active, not recruiting | |||
| Effects of a Mindfulness-Based Intervention on Symptoms and Signs, Well-Being and Health in Patients With Chronic Heart Failure[NCT04871178] | 50 participants (Actual) | Interventional | 2010-10-10 | Completed | |||
| A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037] | Phase 3 | 318 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.88 |
| Carvedilol Controlled Release | -0.86 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 24.00 |
| Carvedilol Controlled Release | 53.37 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.20 |
| Carvedilol Controlled Release | -0.45 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.33 |
| Carvedilol Controlled Release | -0.36 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.76 |
| Carvedilol Controlled Release | -0.83 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .05 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .08 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -42.22 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -18.29 |
| Carvedilol Controlled Release | -20.57 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -43.00 |
Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | mL/m^2 (Mean) |
|---|---|
| Coreg Immediate Release | -18.36 |
| Coreg Controlled Release | -20.81 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 9.5 |
| Carvedilol Controlled Release | -9.29 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .07 |
| Carvedilol Controlled Release | .05 |
SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)
| Intervention | number of SAEs (Number) |
|---|---|
| Carvedilol Immediate Release | 40 |
| Carvedilol Controlled Release | 35 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | subjects in each treatment group (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Entry (10mg Coreg CR, 3.125mg Coreg IR) | Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR) | End of Study (10mg Coreg CR, 3.125mg Coreg IR) | Study Entry (20mg Coreg CR, 6.25mg Coreg IR) | Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR) | End of Study (20mg Coreg CR, 6.25mg Coreg IR) | Study Entry (40mg Coreg CR, 12.5mg Coreg IR) | Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR) | End of Study (40mg Coreg CR, 12.5mg Coreg IR) | Study Entry (80mg Coreg CR, 25mg Coreg IR) | Maintenance Entry (80mg Coreg CR, 25mg Coreg IR) | End of Study (80mg Coreg CR, 25mg Coreg IR) | |
| Carvedilol Controlled Release | 83 | 0 | 4 | 39 | 9 | 16 | 27 | 16 | 22 | 4 | 114 | 111 |
| Carvedilol Immediate Release | 79 | 0 | 7 | 61 | 13 | 16 | 21 | 12 | 21 | 4 | 116 | 121 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | participants in each treatment group (Number) | ||
|---|---|---|---|
| Hospitalization for Heart Failure | Hospitalization Due to Any Cause | Hospitalization or Death | |
| Carvedilol Controlled Release | 6 | 29 | 29 |
| Carvedilol Immediate Release | 6 | 31 | 32 |
11 reviews available for carvedilol and Disease Exacerbation
| Article | Year |
|---|---|
What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Blood Pressure; Carbazoles; Carve | 2009 |
β-blockers in stage B: a precursor of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular System; C | 2012 |
Antiadrenergic therapy in the control of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Cardi | 2005 |
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2007 |
Effects of beta-adrenergic blockade on survival of patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Clinical Trials as Topic; Disease Prog | 1997 |
Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Carbazoles; Carved | 1998 |
Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Antioxidants; Apoptosis; Carbazoles; Carvedilol; Disease Progression; H | 1998 |
Progression from hypertension to heart failure. Mechanisms and management.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Disease Progression; Heart Failure; Humans; Hyp | 1999 |
Beta-blockers: the new standard of therapy for mild heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Diastole; Disease Progression; | 2000 |
Sympathetic activation and the role of beta-blockers in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Disease Progression; Heart Failure; Hemodynamic | 1999 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
7 trials available for carvedilol and Disease Exacerbation
| Article | Year |
|---|---|
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype.
Topics: Antihypertensive Agents; Atrial Natriuretic Factor; Biopsy; Calcium-Transporting ATPases; Carbazoles | 2002 |
Symptoms in patients with heart failure are prognostic predictors: insights from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Disease Progression; Dou | 2005 |
Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Diastole; Disease Progression; Double-Bli | 2005 |
Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles | 2006 |
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Cardiac Output, | 1996 |
Carvedilol treatment of kidney graft recipients with chronic rejection.
Topics: Adult; Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Cholesterol, HDL; Cholesterol, LDL; Ch | 1999 |
16 other studies available for carvedilol and Disease Exacerbation
| Article | Year |
|---|---|
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2020 |
Digoxin Toxicity in a Neonate Caused by the Interaction with Carvedilol.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Carvedilol; Digoxin; Disease Progression; Heart | 2017 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
Update on pharmacological advances.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Disea | 2004 |
Attending rounds: a patient with accelerated hypertension and an atrophic kidney.
Topics: Aged; Amides; Antihypertensive Agents; Atherosclerosis; Atrophy; Blood Pressure; Carbazoles; Carvedi | 2014 |
Pulmonary capillary hemangiomatosis: a diagnostic challenge.
Topics: Carbazoles; Carvedilol; Delayed Diagnosis; Disease Progression; Furosemide; Granuloma, Pyogenic; Hum | 2015 |
Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol | 2015 |
Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Disease Progression; Female; Genotype; Ha | 2008 |
Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; Blood Pressu | 2009 |
Cardiac magnetic resonance imaging and management of dilated cardiomyopathy in a Duchenne muscular dystrophy manifesting carrier.
Topics: Adult; Biomarkers; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Child; Creatine Kinase; Disease | 2009 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
Carvedilol attenuates the progression of alcohol fatty liver disease in rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Vessels; Blotting, Western; Carbazoles; Carvedilol; Cent | 2012 |
Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy.
Topics: Animals; Antibiotics, Antineoplastic; Antihypertensive Agents; Blood Pressure; Captopril; Carbazoles | 2005 |
Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy.
Topics: Animals; Body Weight; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Disease Progression; Endomyoc | 2000 |
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Chron | 2001 |